1,25-Dihydroxyvitamin D 3 regulates PTHrP expression via transcriptional, post-transcriptional and post-translational pathways

Molecular and Cellular Endocrinology

Volumn 342, Issue 1-2, 2011, Pages 32-40

  Bhatia, Vandanajay ^a   Mula, Ramanjaneya V ^a   Falzon, Miriam ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

1,25 Dihydroxyvitamin D 3; Negative vitamin D response element; Parathyroid hormone related protein; Prostate cancer; Vitamin D receptor

Indexed keywords

ALCOHOL; ANDROGEN; CALCITRIOL; MESSENGER RNA; PARATHYROID HORMONE RELATED PROTEIN; SMALL INTERFERING RNA; VITAMIN D RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL LEVEL; CONTROLLED STUDY; DOWN REGULATION; GENE ACTIVITY; GENE EXPRESSION REGULATION; GENE REPRESSION; GENETIC STABILITY; HUMAN; HUMAN CELL; MALE; ONCOGENE; PARATHYROID HORMONE RELATED PROTEIN GENE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN PROCESSING; TRANSCRIPTION REGULATION;

CALCITRIOL; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MALE; PARATHYROID HORMONE-RELATED PROTEIN; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, CALCITRIOL; RNA INTERFERENCE; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC;

EID: 79960847097     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.05.025     Document Type: Article

References (76)

1. Abe M., Akeno N., Ohida S., Horiuchi N. Inhibitory effects of 1,25-dihydroxyvitamin D3 and 9-cis-retinoic acid on parathyroid hormone-related protein expression by oral cancer cells (HSC-3). J. Endocrinol. 1998, 156:349-357.
2. Alizadeh M., Gelfman G.M., Bench S.R., Hjelmeland L.M. Expression and splicing of FGF receptor mRNAs during ARPE-19 cell differentiation in vitro. Invest. Ophthalmol. Vis. Sci. 2000, 41:2357-2362.
3. Berruti A., Piovesan A., Torta M., Raucci C.A., Gorzegno G., Paccotti P., Dogliotti L., Angeli A. Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiographic appearances and disease extension. Br. J. Cancer 1996, 73:1581-1587.
4. Bhatia V., Saini M.K., Shen X., Bi L.X., Qiu S., Weigel N.L., Falzon M. EB1089 inhibits the PTHrP-enhanced bone metastasis and xenograft growth of human prostate cancer cells. Mol. Cancer Ther. 2009, 8:1787-1798.
5. Bird A.P. CpG-rich islands and the function of DNA methylation. Nature 1986, 321:209-213.
6. Blutt S.E., Allegretto E.A., Pike J.W., Weigel N.L. 1,25-Dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology 1997, 138:1491-1497.
7. Bouillon R., Bischoff-Ferrari H., Willett W. Vitamin D and health: perspectives from mice and man. J. Bone Min. Res. 2008, 23:974-979.
8. Broadus A.E., Stewart A.F. Parathyroid hormone-related protein structure, processing and physiological actions. The Parathyroids 1994, Raven Press, New York. J.P. Bilezikian (Ed.).
9. Bubendorf L., Schopfer A., Wagner U., Sauter G., Moch H., Willi N., Gasser T.S., Mihatsch M.J. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum. Path. 2000, 31:578-583.
10. Cataisson C., Gordon J., Roussiére M., Abdalkhani A., Lindemann R., Dittmer J., Foley J., Bouizar Z. Ets-1 activates parathyroid hormone-related protein gene expression in tumorigenic breast epithelial cells. Mol. Cell. Endocrinol. 2002, 204:155-168.
11. Christados S., Raval-Pandya M., Wernyj R.P., Yang W. Genomic mechanisms involved in the pleiotropic actions of 1,25-dihydroxyvitamin D3. Biochem. J. 1996, 316:361-371.
12. Chung I., Han G., Seshadri M., Gillard B.M., Yu W.D., Foster B.A., Trump D.L., Johnson C.S. Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Res. 2009, 69:967-975.
13. Deftos L.J. Prostate carcinoma: production of bioactive factors. Cancer 2000, 88:3002-3008.
14. De Luca H.F. Overview of general physiologic features and functions of vitamin D. Am. J. Clin. Nutr. 2004, 80:1689S-1696S.
15. Dhawan J., Lichtler A.C., Rowe D.W., Farmer S.R. Cell adhesion regulates pro-alpha 1(I) collagen mRNA stability and transcription in mouse fibroblasts. J. Biol. Chem. 1991, 266:8470-8475.
16. Dougherty K.M., Blomme E.A.G., Koh A.J., Henderson J.E., Pienta K.J., Rosol T.J., McCauley L.K. Parathyroid hormone-related protein as a growth regulator of prostate carcinoma. Cancer Res. 1999, 59:6015-6022.
17. Eccles S.A. Targeting key steps in metastatic tumour progression. Curr. Opin. Genetics Dev. 2005, 15:77-86.
18. El Abdaimi K., Papavasilou V., Rabbani S.A., Rhim J.S., Goltzmann D., Kremer R. Reversal of hypercalcemia with the vitamin D analogue EB1089 in a human model of squamous cancer. Cancer Res. 1999, 59:3325-3328.
19. Garneau N.L., Wilusz J., Wilusz C.J. The highways and byways of mRNA decay. Nat. Rev. Mol. Cell Biol. 2007, 8:113-126.
20. Glatz J.A., Heath J.K., Southby J., O'Keeffe L.M., Kiriyama T., Moseley J.M., Martin T.J., Gillespie M.T. Dexamethasone regulation of parathyroid hormone-related protein (PTHrP) expression in a squamous cancer cell line. Mol. Cell. Endocrinol. 1994, 101:295-306.
21. Guhaniyogi J., Brewer G. Regulation of mRNA stability in mammalian cells. Gene 2001, 265:11-23.
22. Guise T.A., Mohammad K.S., Clines G., Stebbins E.G., Wong D.H., Higgins L.S., Vessella R., Corey E., Padalecki S., Suva L., Chirgwin J.M. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin. Cancer Res. 2006, 12(20 Suppl.):6213s-6216s.
23. Hall C.L., Kang S., MacDougals O.A., Keller E.T. Role of Wnts in prostate cancer bone metastases. J. Cell. Biochem. 2006, 97:661-672.
24. Hall C.L., Bafico A., Dia J., Aaronson S.A., Keller E.T. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res. 2005, 65:7554-7560.
25. Hamzaoui H., Risk-Rabin M., Gordon J., Offutt C., Bertherat J., Bouizar Z. PTHrP P3 promoter activity in breast cancer cell lines: role of Ets1 and CBP (CREB binding protein). Mol. Cell. Endocrinol. 2007, 268:75-84.
26. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2005, 100:57-70.
27. Haq M., Kremer R., Goltzman D., Rabbani S.A. A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo. J. Clin. Invest. 1993, 91:2416-2422.
28. Holick M.F. Vitamin D: a millennium perspective. J. Cell. Biochem. 2003, 88:296-307.
29. Holt E.H., Vasavada R.C., Bander N.H., Broadus A.E., Philbrick W.M. Region-specific methylation of the parathyroid hormone-related peptide gene determines its expression in human renal carcinoma cell lines. J. Biol. Chem. 1993, 268:20639-20645.
30. Ignowski J.M., Schaffer David V. Kinetic analysis and modeling of firefly luciferase as a quantitative reporter gene in live mammalian cells. Biotechnol. Bioeng. 2004, 86:827-834.
31. Iwamura M., Wu R., Abrahamsson P.A., di Sant'Agnese P.A., Cockett A.T., Deftos L.J. Parathyroid hormone-related protein is expressed by prostatic neuroendocrine cells. Urology 1994, 43:667-674.
32. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J. Cancer statistics. CA Cancer J. Clin. 2007, 57:1873-1882.
33. Jensen S.S., Madsen M.W., Lukas J., Binderup L., Bartek J. Inhibitory effects of 1α,25-dihydroxyvitmain D3 on the G1-S phase-controlling machinery. Mol. Endocrinol. 2001, 15:1370-1380.
34. Kallay E., Pietschmann P., Toyokuni S., Bajna E., Hahn P., Mazzucco K., Bieglmayer C., Kato S., Cross H.S. Characterization of a vitamin D receptor knockout mouse as a model of colorectal hyperproliferation and DNA damage. Carcinogenesis 2001, 22:1429-1435.
35. Karmali R., Nus-de-Wolf N., Beyer I., Hendy G.N., Bergmann P. 1,25-Dihydroxyvitmain D3 inhibits parathyroid hormone-related peptide mRNA expression in fetal rat long bones in culture. In Vitro Cell. Dev. Biol. 1999, 35:296-298.
36. Kasper S., Sheppard P.C., Yan Y., Pettigrew N., Borowsky A.D., Prins G.S., Dodd J.C., Duckworth R.J., Matusik R.J. Development, progression and androgen-dependence of prostate tumors in probasin-large-T-antigen transgenic mice: a model for prostate cancer. Lab. Invest. 1998, 78:319-333.
37. Keller E.T., Zhang J., Cooper C.R., Smith P.C., McCauley L.K., Pienta K.J., Taichman R.S. Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev. 2001, 20:333-349.
38. Kramer S., Reynolds F.J., Castillo M., Valenzuela D.M., Thorikay M., Sorvillo J.M. Immunological identification and distribution of parathyroid hormone-like protein polypeptides in normal and malignant tissues. Endocrinology 1991, 128:1927-1937.
39. Kip1 stabilization and G1 arrest by 1,25-dihydroxyvitamin D3 in ovarian cancer cells mediated through down-regulation of cyclin E/cyclin-dependent kinase 2 and Skp1-Cullin-F-box protein/Skp2 ubiquitin ligase. J. Biol. Chem. 2004, 279:25260-25267.
40. Luparello C., Schilling T., Cirincione R., Pucci-Minafra I. Extracellular matrix regulation of PTHrP and PTH/PTHrP receptor in a human breast cancer cell line. FEBS Lett. 1999, 463:265-269.
41. Mangin M., Ikeda K., Dreyer B.E., Broadus A.E. Identification of an upstream promoter of the human parathyroid hormone-related peptide gene. Mol. Endocrinol. 1990, 4:851-858.
42. Mantell D.J., Ownes P.E., Bundred N.J., Mawer E.B., Canfiels A.E. 1α,25-Dihydroxyvitamin D3 inhibits angiogenesis in vitro and in vivo. Circ. Res. 2000, 87:214-220.
43. Massfelder T., Lang H., Schordan E., Lindner V., Rothhut S., Welsch S., Simon-Assmann P., Barthelmebs M., Jacqmin D., Helwig J.-J. Parathyroid hormone-related protein is an essential growth factor for human clear cell renal carcinoma and a target for the von Hippel-Lindau tumor suppressor gene. Cancer Res. 2004, 64:180-188.
44. Masuyama H., MacDonald P.N. Proteasome-mediated degradation of the vitamin D receptor (VDR) and a putative role for SUG1 interaction with the AF-2 domain of VDR. J. Cell. Biochem. 1998, 71:429-440.
45. Mathiasen I.S., Colston K.W., Binderup L. EB1089: a novel vitamin D analogue, has strong antiproliferative and differentiation inducing effects of cancer cells. J. Steroid Biochem. Mol. Biol. 1993, 46:365-371.
46. Meerovitch K., Wing S., Goltzman D. Preproparathryoid hormone-related protein, a secreted peptide, is a substrate for the ubiquitin proteolytic system. J. Biol. Chem. 1997, 272:6706-6713.
47. Meerovitch K., Wing S., Goltzman D. Preproparathyroid hormone-related protein is associated with the chaperone protein BiP and undergoes proteasome-mediated degradation. J. Biol. Chem. 1998, 273:21025-21030.
48. 2+ pump mRNA stability in cardiac and smooth muscle: role of the 3′-untransloated region. Am. J. Physiol. Cell Physiol. 2002, 283:C560-C568.
49. Mordan-McCombs S., Brown T., Wang W.-L.W., Gaupel A.-C., Welsh J., Tenniswood M. Tumor progression in the LPB-Tag transgenic model of prostate cancer is altered by vitamin D receptor and serum testosterone levels. J. Steroid Biochem. Mol. Biol. 2010, 121:368-371.
50. Nishishita T., Okazaki T., Ishikawa T., Igarashi T., Hata K., Ogata E., Fujita T. A negative vitamin D response DNA element in the human parathyroid hormone-related peptide gene binds to vitamin D receptor along with Ku antigen to mediate negative gene regulation by vitamin D. J. Biol. Chem. 1998, 273:10901-10907.
51. Nothnick W.B., Healy C., Hong X. Steroidal regulation of uterine miRNAs is associated with modulation of the miRNA biogenesis components Exportin-5 and Dicer1. Endocrinology 2010, 37:265-273.
52. Parker R., Sheth U. P bodies and the control of mRNA translation and degradation. Mol. Cell 2007, 25:635-646.
53. Peehl D.M., Feldman D. The role of vitamin D and retinoids in controlling prostate cancer progression. Endocr. Relat. Cancer 2003, 10:131-140.
54. Polek T.C., Weigel N.L. Vitamin D and prostate cancer. J. Androl. 2002, 23:9-17.
55. Rana A., Chisholm G.D., Khan M., Sekharjit S.S., Merrick M.V., Ellton R.A. Patterns of bone metastasis and their prognostic significance in patients with carcinoma of the prostate. Br. J. Urol. 1993, 72:933-936.
56. Schordan E., Welsch S., Rothhut S., Lambert A., Barthelmers M., Helwig J.-J., Massfelder T. Role of parathyroid hormone-related protein in the regulation of stretch-induced renal vascular smooth muscle cell proliferation. J. Am. Soc. Nephrol. 2004, 15:3016-3025.
57. Schwartz G.G. Vitamin D and intervention trials in prostate cancer: from theory to therapy. Ann. Epidemiol. 2009, 19:96-102.
58. Sellers R.B., Capen C.C., Rosol T.J. Messenger RNA stability of parathyroid hormone-related protein regulated by transforming growth factor-beta 1. Mol. Cell. Endocrinol. 2002, 25:37-46.
59. Sellers R.S., Luchin A.I., Richard V., Brena R.M., Lima D., Rosol T.J. Alternative splicing of parathyroid hormone-related protein mRNA: expression and stability. Mol. Cell. Endocrinol. 2004, 33:227-241.
60. Shen X., Rychahou P.G., Evers B.M., Falzon M. PTHrP increases xenograft growth and promotes integrin α6β4 expression and Akt activation in colon cancer. Cancer Lett. 2007, 258:241-252.
61. Shen X., Mula R.V.R., Li J., Weigel N.L., Falzon M. PTHrP contributes to the anti-proliferative and integrin α6β4-regulating effects of 1,25-dihydroxyvitamin D3. Steroids 2007, 72:930-938.
62. Southby J., O'Keefe L.M., Martin T.J., Gillespie M.T. Alternative promoter usage and mRNA splicing pathways for parathyroid hormone-related protein in normal tissues and tumours. Br. J. Cancer 1995, 72:702-707.
63. Stewart L.V., Weigel N.L. Vitamin D and prostate cancer. Exp. Biol. Med. (Maywood) 2004, 229:277-284.
64. Suzuki K., Kelleher A.D. Transcriptional regulation by promoter targeted RNAs. Curr. Top. Med. Chem. 2009, 9:1079-1087.
65. Tashiro K., Ishii C., Ryoji M. Role of distal upstream sequence in vitamin D-induced expression in human CYP24 gene. Biochem. Biophys. Res. Commun. 2007, 358:259-265.
66. Thalmann G.N., Anezinis P.E., Chang S.M., Zhau H.E., Kim E.E., Hopwood V.L., Pathak S., von Eschenbach A.C., Chung L.W. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 1994, 54:2577-2581.
67. Tovar Sepulveda V.A., Falzon M. Parathyroid hormone-related protein enhances PC-3 prostate cancer cell growth via both autocrine/paracrine and intracrine pathways. Reg. Pept. 2002, 105:109-120.
68. Tovar Sepulveda V.A., Falzon M. Prostate cancer cell type-specific regulation of the human PTHrP gene via a negative VDRE. Mol. Cell. Endocrinol. 2003, 204:51-64.
69. Tovar Sepulveda V.A., Weigel N.L., Falzon M. Prostate cancer cell type-specific involvement of the VDR and RXR in regulation of the human PTHrP gene via a negative VDRE. Steroids 2006, 71:102-115.
70. Vasavada R.C., Wysolmerski J.J., Broadus A.E., Philbrick W.M. Identification and characterization of a GC-rich promoter of the human parathyroid hormone-related peptide gene. Mol. Endocrinol. 1993, 7:273-282.
71. Vinholes J., Coleman R., Eastell R. Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treat. Res. 1996, 22:289-331.
72. Washington M.N., Kim J.-S., Weigel N.L. 1α25-Dihydroxyvitamin D3 inhibits C4-2 prostate cancer cell growth via a retinoblastoma protein (Rb)-independent G1 arrest. Prostate 2011, 71:98-110.
73. Welsh J. Vitamin D and breast cancer: insights from animal models. Am. J. Clin. Nutr. 2004, 80:1721S-1724S.
74. Wu H.C., Hsieh J.T., Gleave M.E., Brown N.M., Pathak S., Chung L.W. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int. J. Cancer 1994, 57:406-412.
75. Zhuang S.-H., Burnstein K.L. Antiproliferative effect of 1α,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 1998, 139:1197-1207.
76. Zhuang S.H., Schwartz G.G., Cameron D., Burnstein K.L. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol. Cell. Endocrinol. 1997, 126:83-90.